IMNN-001 clinical trials
IMNN-001 is named as an intervention in 3 current clinical trials in our USA and Canada registers. 2 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Imunon. The most-studied condition is Fallopian Tube Cancer.
Patient leaflets for IMNN-001
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of IMNN-001
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06915025 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer
|
Phase 3 | Recruiting | Imunon | USA |
|
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05739981 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
|
Phase 1/2 | Recruiting | Imunon | USA |
|
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
NCT03393884 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
|
Phase 1/2 | Active, closed | Imunon | USA, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with IMNN-001
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Imunon | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in Canada | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about IMNN-001 trials
How many clinical trials are testing IMNN-001?
3 current trials in our USA and Canada registers name IMNN-001 (also registered as GEN-1) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are IMNN-001 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors IMNN-001 clinical trials?
The lead sponsor is Imunon. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IMNN-001 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IMNN-001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IMNN-001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.